about
The changing landscape of biosimilars in rheumatologyReview of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders.Nomenclature and traceability debate for biosimilars: small-molecule surrogates lend support for distinguishable nonproprietary names.The totality-of-the-evidence approach to the development and assessment of GP2015, a proposed etanercept biosimilar.[Biosimilars in rheumatology. Development and results of clinical trials].
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Biosimilars: how similar?
@en
type
label
Biosimilars: how similar?
@en
prefLabel
Biosimilars: how similar?
@en
P2860
P356
P1476
Biosimilars: how similar?
@en
P2093
P2860
P304
P356
10.1111/IMJ.12292
P577
2014-03-01T00:00:00Z